Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-03-22
2011-03-22
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S171000, C514S178000, C514S182000, C514S899000
Reexamination Certificate
active
07910570
ABSTRACT:
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
REFERENCES:
patent: 5183814 (1993-02-01), Dukes
patent: 5550107 (1996-08-01), Labrie
patent: 6265393 (2001-07-01), Heinrichs
patent: 2002/0156059 (2002-10-01), Elliesen
patent: 2004/0120956 (2004-06-01), Song et al.
patent: 0451869 (1995-12-01), None
patent: 95/17194 (1995-06-01), None
patent: 95/20972 (1995-08-01), None
patent: 99/63973 (1999-12-01), None
patent: 00/07599 (2000-02-01), None
patent: 02/30355 (2002-04-01), None
patent: 02/072106 (2002-09-01), None
patent: 02/074315 (2002-09-01), None
patent: 03/015872 (2003-02-01), None
patent: 03/017973 (2003-03-01), None
patent: 03/017974 (2003-03-01), None
patent: 03/039455 (2003-05-01), None
patent: 03/061665 (2003-07-01), None
patent: 03/082254 (2003-10-01), None
patent: 03/082299 (2003-10-01), None
patent: 03/082336 (2003-10-01), None
Teirney et al. Reviews in Gynaecological Practice 2 (2002), pp. 91-98.
Bulun et al. Human Reproduction Update (2002). vol. 6, No. 5,pp. 413-418.
Taiwan Office Action, 3 pages.
Office Action mailed May 28, 2008 for Application No. 1-2005-501405, Applicant AstraZeneca AB, filed Aug. 1, 2005, Republic of the Phillipines, Intellectual Property Phillipines, Bureau of Patents, Medical Science & Biotechnology Examining Division.
Office Action dated Oct. 1, 2007 for Russian Federation Patent Application No. 2005 127 667, Applicant AstraZeneca AB.
ACOG; Obstet Gynecol, 405-407, 112, (year 2008).
ASRM; Fertility and Sterility, 2006, S18-S27, 86.
ASRM; Fertility and Sterility, 2006, S156-S160, 86.
ASRM; Fertility and Sterility, 1997, 817-821, 67.
Abrao et at; Human Reproduction, 2007, 3092-3097, 22.
Acien et al; Fertility and Sterility, 2007, 32-8, 88.
Ailawadi et al; Fertility and Sterility, 2004, 290-296, 81.
Amsterdam, Fertility and Sterility, 2005, 300-304, 84.
Attar et al; Fertility and Sterility, 2006, 1307-1318, 85.
Attar et al; Comtemp Ob/Gyn, 2006, 82-89.
Attar et al; Human Reprod Update, 2006, 49-56, 12.
Ballard et al; Fertility and Sterility, 2006, 1296-1306, 86.
Bertelsen et al; Ind J Cancer, 2006, 1372-1375, 120.
Bianconi et al; Fertility and Sterility, 2007,1285-1287, 85.
Biberoglu et al; Am J Obstet Gynecol, 1981, 645-654, 139.
Bulun et al; J Clin Endo Metab, 1993, 1458-1463, 76.
Bulun et al; Ann NY Acad Sci, 2002, 75-85, 955.
Bulun et al; J Molec Endocrinol, 2000, 35-42, 25.
Bulun et al; Seminar in Reprod Med, 2004, 45-50, 22.
Bulun et al; Pharmacol Rev, 2005, 359-383, 57.
Bulun et al; Endocrine-Related Cancer, 1999, 293-103, 6.
Bulun et al; Molec Cell Endocrinol, 2006, 94-103, 248.
Carbognin et al; Radiol Med, 2006, 687-701, 111.
Cheng et al; Am J Obstet Gynecol, 2007, e1.391-e8.381, 196.
Child et al; Drugs, 2001, 1735-1750, 61.
Chlouber et al; Expert Opinion Investig Drugs, 2006, 399-407, 15.
Crosignani et al; Human Reprod Update, 2006, 179-189, 12.
Crosignani et al; Human Reprod, 2006, 248-256, 21.
Dassen et al; Human Reprod, 2007, 3148-3158, 12.
Del Frate et al; RadioGraphics, 2006, 1705-1718, 26.
Ebert et al; Obstet Gynecol, 2005, 144-150, 122.
Fang et al; Fertility and Sterility, 2004, 673-678, 82.
Gurates et al; Seminar in Reprod Med, 2003, 125-134, 21.
Hastings et al; Reprod Biol Endo, 2006, S7, 4.
Heiler et al; Fertility and Sterility, 2006, 1516-1518, 85.
Ishihara et al; Fertility and Sterility, 2003, 735-42, 79.
Kyama et al; Fertility and Sterility, 2008, 301-310, 89.
Meresman et al; Fertility and Sterility, 2005, 459-463, 84.
Mukakami et al, Fertility and Sterility, 2006, 291-297, 86.
Nobel et al; J Clin Endo Metab, 1996, 174-179, 81.
Nobel et al; J Clin Endo Metab, 1997, 600-606, 82.
Sharpe-Timms et al; NY Acad Sci, 2001, 131-147, 943.
Simpson et al; NY Acad Sci, 2001, 58-67, 949.
Smuc et al; Gynecol Endo, 2007, 105-111, 23.
Velasco et al; Molec Human Reprod, 2006, 377-381, 12.
Wu et al; Am J Pathol, 2005, 1061-1069, 167.
Banu et al., Short title: COX-2 in endometriosis, 2007, 1-29.
Falconer et al., Endometriosis and Genetic Polymorphisms, 2007, 616-628, 62.
Sharp-Timms et al., Using rats as a Research Model for the study of endometriosis, 318-327.
Yano et al., Studies on the Effect of the New Non-steroidal Aromatase Inhibitor Fadrozole Hydrochloride in an Endometriosis Model in Rats, 1996, 192-195, 46.
Yue et al; Cancer Res, 1998, 927-932, 58.
Zeitoun et al; Fertility and Sterility, 1999, 961-969, 72.
Zeitoun et al; Molec Endocrin, 1999, 239-253, 13.
English Language Translation of Portion of Nov. 19, 2009 Office Action for Corresponding Japanese Patent Application No. 2006-502229 Relevant to References Cited Therein.
Takayama, K. et al ., “Treatment of Severe Postmenopausal Endometriosis with an AromataseInhibitor”, Fertility and Sterility, Apr. 1998, vol. 69, No. 4, pp. 709-713.
Asada, H. et al., “Medical Management of Endometriosis-Associated Infertility and Endometriosis Associated Pain”, Sanfujinka Chiryo (Obstetrical and Gynecological Therapy), Oct. 1, 2001, vol. 83, No. 4, pp. 443-450.
Uemura, T. et al., “Current Situation of Medical Care for Endometriosis: Chemotherapy for Endometriosis” Sanka To Fujinka (Obstetrics and Gynecology Tokyo), Aug. 1987, vol. 54, No. 8, pp. 1457-1463.
Archer, D. F. et al ., “A New Low-Dose Monophasic Combination Oral Contraceptive (AlesseTM) with Levonorgestrel 100 μg and Ethynyl Estradiol 20 μg”, Contraception, Mar. 1997, vol. 55, No. 3, pp. 139-144.
Fang, Z et al ‘Genetic or Enzymatic Disruption of Aromatase Inhibits the Growth of Ectopic Uterine Tissue’ Journal of Clinical Endocrinology & Metabolism, 2002, pp. 3460-3466, vol. 87(7).
Rice, V, M. ‘Conventional Medical Therapies for Endometriosis’ Annals of the New York Academy of Sciences, 2002, pp. 343-352, vol. 955.
Olive, D, L & Pritts, E, A ‘Treatment of Endometriosis’ New England Journal of Medicine, 2001, pp. 266-275, vol. 345(4).
Bulun, S, E et al ‘Molecular basis for treating endometriosis with aromatase inhibitors’ Human Reproduction Update, 2000, pp. 413-418, vol. 6(5).
Zumpe, D et al ‘Behavioural responses to depo-provera, fadrozole, and estradiol in castrated, testosterone-treated cynomolgus monkeys (Macaca fascicularis): the involvement of progestin receptors’ Physiology and Behaviour, 1996, pp. 531-540, vol. 60/2.
Bulun, S, E et al ‘Aromatase as a therapeutic target in endometriosis’ Trends in Endocrinology and Metabolism, 2000, pp. 22-27, vol. 11(1).
Surrey, E et al ‘Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up’ Obstet & Gynecol, 2002, pp. 709-719, vol. 99(5).
Mahutte, N, G et al ‘Medical management of endometriosis-associated pain’ Obstetrics and Gynecology Clinics of North America, 2003, pp. 133-150, vol. 30/1.
Genazzani, A, R et al ‘Hormone replacement therapy and cancer. International menopause society workshop’ Gynecological Endocrinology, 2001, pp. 453-465, vol. 15/6.
Ailawadi Radhika, K et al ‘Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: A pilot study’ Fertility and Sterility, 2004, pp. 290-296, vol. 81(2).
Bulun Serdar E.
Rubin Stephen
Astrazeneca AB
Jean-Louis Samira
Wang Shengjun
LandOfFree
Composition comprising a combination of an aromatase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition comprising a combination of an aromatase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition comprising a combination of an aromatase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679354